How long does risk-reducing endocrine therapy take to work for a BRCA gene mutation?

A BRCA1 or BRCA2 mutation can increase the chance of certain cancers, but endocrine therapy is not a treatment for an inherited mutation itself. Depending on your breast tissue, age, medical history and previous procedures, a clinician may discuss medicine that changes hormone signalling. The aim is to lower the chance of hormone-sensitive breast cancer developing; it does not remove every cancer risk.

Because the medicine works through ongoing hormone effects, clinicians judge benefit across time rather than by symptoms or a single scan. Taking it consistently matters, and regular breast assessment remains part of care. A genetic counsellor or oncology team can explain whether the proposed medicine fits your particular BRCA-related risk.

Before starting, review medicines, pregnancy plans, menstrual status, bone health and any history of blood clots or other relevant conditions. Ask how to take each dose and what to do after a missed dose. Keep scheduled clinical reviews so side effects can be weighed against the prevention goal. Do not stop or restart treatment without discussing it with the prescribing team; an alternative plan may be possible if symptoms interfere with daily life.

Contact your care team promptly for troublesome bleeding, a new breast change, severe mood changes or symptoms that make continuing the medicine difficult. Seek urgent medical help for sudden chest pain, difficulty breathing, coughing blood, or new one-sided leg swelling and pain, because these can signal a serious problem. Your team can tell you which symptoms need same-day assessment.

Which endocrine medicine is appropriate for my BRCA1 or BRCA2-related risk? When will we review whether I am tolerating it? What breast screening and risk-reduction options should continue alongside it? Which side effects should prompt a call, and what alternatives are available if they persist?